DRTS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

DRTS ▲ +39.92% at T+5d

LONG call ✓ call won +39.92% · α vs SPY +37.93% · entry $7.39 → $10.34

Next anchor: T+20d in 10d

Last close $10.04 (close May 22) · +35.86% from $7.39 entry

Entry anchored
May 5, 04:19 AM ET
via Databento tick

T+1d

+2.71%

call +2.71% · α +1.32%

$7.59

settled 18d ago

T+5d

+39.92%

call +39.92% · α +37.93%

$10.34

settled 12d ago

T+20d

—

call — · α —

—

in 10d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Alpha Tau Medical announced that an abstract on Alpha DaRT in combination with pembrolizumab for elderly patients with head and neck cancer has been accepted for a podium presentation at the AHNS International Conference (July 18-22, 2026). This marks a strategic milestone for the company's combination therapy program, building on prior monotherapy data.

Actionable Insight

Monitor the AHNS presentation on July 21, 2026, for top-line efficacy and safety data. Positive results could drive near-term interest in DRTS, but regulatory and commercialization timelines remain distant.

Key Facts

Abstract accepted for podium presentation at AHNS International Conference on Head and Neck Cancer (July 21, 2026)
Study evaluates Alpha DaRT + pembrolizumab in elderly patients with locally advanced/metastatic HNSCC
Complete top-line data to be presented; builds on prior monotherapy safety data
Elderly HNSCC patients have limited treatment options, representing a significant unmet need

Financial Impact

No financial data provided; potential upside if combination data is positive, but no revenue impact expected near-term

Risk Factors

Clinical trial data may not meet expectations
Competition from other intratumoral therapies and immunotherapies
Regulatory approval and reimbursement uncertainties

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

80% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3287848

7 reports for DRTS

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+20▲ +40.10%Apr 23, 2026

Filters

Reports for DRTS — sortable, filterable
	Type				Now
May 11, 2026 12d ago	Press Release BULLISH ★ 7/10	$10.34 $10.03	▼ −3.00%	▼ −2.91%	$10.04 (−2.90%)
May 8, 2026 15d ago	Press Release BULLISH ★ 7/10	$8.51 $10.41	▲ +22.33%	▲ +20.86%	$10.04 (+17.98%)
May 5, 2026 18d ago	Press Release BULLISH ★ 5/10	$7.39 $10.34	▲ +39.92%	▲ +37.93%	$10.04 (+35.86%)
May 4, 2026 19d ago	Press Release BULLISH ★ 7/10	$7.53 $10.34	▲ +37.32%	▲ +34.38%	$10.04 (+33.33%)
Apr 27, 2026 26d ago	Press Release MIXED ★ 6/10	$7.91 $7.53	▼ −4.80%	▼ −5.20%	$10.04 (+26.93%)
Apr 23, 2026 4w ago	Press Release BULLISH ★ 7/10	$7.98 $7.37	▼ −7.64%	▼ −9.12%	$10.04 (+25.81%)
Mar 9, 2026 10w ago	Press Release MIXED ★ 6/10	$6.84 $7.47	▲ +9.21%	▲ +10.12%	$10.04 (+46.78%)

US Market Status

Market Closed — Opens Tue (35h 14m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access